FFR Benefit Prompts St. Jude to Halt FAME II Study

Courtesy MedPage Today Surgery  Wed, 01/18/2012 - 16:16

(MedPage Today) -- The sponsor of the FAME II trial, which is assessing the efficacy of fractional flow reserve (FFR) as a tool to improve stenting outcomes, said it is halting enrollment after an analysis revealed a significant benefit for patients in the FFR arm.


 

More related items

Model Explains Efficacy of HIV Drugs (CME/CE)
(MedPage Today) -- Any HIV therapy that reduces the risk of an immune cell being infected by a factor of at least 100,000 is enough to keep the virus in check, researchers reported.

Cancer sequencing initiative discovers mutations tied...
(St. Jude Children's Research Hospital) Researchers studying a rare, lethal childhood tumor of the brainstem discovered that nearly 80 percent of the tumors have mutations in genes not...

Gene therapy achieves early success against...
(St. Jude Children's Research Hospital) Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by...

Numi's Bouquet Bamboo Gift Set with Clear Teapot and...

Mania By Giorgio Armani For Men. Eau De Toilette...
Mania Was Created For The Man Seeking A Discreet, Elegant, And Classic Signature Scent. The Classical Freshness Of Mania Is Built Around A Sensual Amber-woody Accord That Brings To Mind Warm...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com